The novel therapy of the medication represents a exciting development in the management of the condition. Unlike existing drugs, tirzepatide affects dual pathways – glucagon-like peptide-1 (GLP-1) and GIP – leading https://tirzepatide-peptide622405.luwebs.com/42973298/tirzepatide-peptide-a-new-frontier-in-diabetes-treatment